Fig. 2

In vitro liver-stage burden quantification and IC₅₀ determination of monoclonal antibodies. Quantification of P. berghei infection burden at 48 hpi under the most inhibitory concentrations (> 90%) in vitro was assessed by a, d qRT-PCR and b, e RLU for PbmCh-luc and Pb-PfCSP(r). Anti-CSP mAbs inhibition of liver-stage development of c PbmCh-luc and f Pb-PfCSP(r) was calculated using RLU and normalized to the control. IC₅₀ curves were computed using Nonlinear regression dose–response modelling in Prism (GraphPad, La Jolla, CA, USA). A Kruskal–Wallis test with Dunn’s multiple comparisons determined statistical significance and is represented as P < 0.05 (*), P < 0.005 (**), P < 0.0005 (***), and P < 0.0001 (****). All results are denoted as median ± 95% CI of triplicate wells in two biological replicates